MedicalResearch.com: Interview withDr. Amit J.Shah MD
Assistant Research Professor
Assistant Professor, Department of Epidemiology
Emory, Rollins School of Public Health
MedicalResearch: What are the main findings of the study?Dr. Shah:We discovered that in a group of patients who were undergoing heart evaluation with coronary angiography, symptoms of depression predicted increased risk of coronary artery disease and death in women aged 55 years or less. This relationship was stronger in these women than older women, as well as in men aged 55 years or less. Over 1 in 4 women aged 55 years or less had moderate to severe depression, which was higher than any other group; these women had over twice the risk of having heart disease or dying over the next 3 years compared to those with none or mild depression.
(more…)
MedicalResearch.com Interview Invitation Dr. Krista Huybrechts MD PhD
Brigham & Women’s Hospital
Department of Medicine
Division of Pharmacoepidemiology & Pharmacoeconomics
Boston, MA 02120
MedicalResearch: What are the main findings of the study?Dr. Huybrechts: In this cohort study including 949,504 pregnant women enrolled in Medicaid, we examined whether the use of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants during the first trimester of pregnancy is associated with increased risks for congenital cardiac defects. In order to control for potential confounding by depression and associated factors, we restricted the cohort to women with a depression diagnosis and used propensity score adjustment to control for depression severity and other potential confounders. We found no substantial increased risk of cardiac malformations attributable to SSRIs. Relative risks for any cardiac defect were 1.25 (95%CI, 1.13-1.38) unadjusted, 1.12 (1.00-1.26) depression-restricted, and 1.06 (0.93-1.22) depression-restricted and fully-adjusted. We found no significant associations between the use of paroxetine and right ventricular outflow tract obstruction (1.07, 0.59-1.93), or the use of sertraline and ventricular septal defects (1.04, 0.76-1.41); two potential associations that had been of particular concern based on previous research findings.
(more…)
MedicalResearch.com Interview with: Nicholas B. King, PhD,
Biomedical Ethics Unit
McGill University
Montreal QC Canada
MedicalResearch: What are the main findings of the study?Dr. King: Unintentional overdoses from prescription opioid painkillers have been rising sharply in the US and Canada during the past two decades, killing thousands of people every year. A lot has been written about the subject in both popular media and scholarly literature, but we still don't have a very good idea of why this has happened. So we tried to objectively and systematically assess evidence for what has contributed to increasing mortality. We found the following:
(1) The evidence base for why mortality has increased is very thin, and more research is urgently required.
(2) We found evidence for at least 17 different causes of increased mortality. We found the most evidence for the following factors: dramatically increased prescription and sales of opioids; increased use of strong, long-acting opioids like oxycodone and methadone; combined use of opioids and other (licit and illicit) drugs and alcohol; and social and demographic characteristics. We found little evidence that internet sales of pharmaceuticals and errors by doctors and patients--factors commonly cited in the media--have played a significant role.
(more…)
MedicalResearch.com Interview with Michele Jacob, Ph.D.
Professor of Neuroscience
Sackler School of Graduate Biomedical Sciences
Tufts University
MedicalResearch: What are the main findings of the study?Dr. Jacob: Autistic-like behaviors and cognitive impairments associate with loss of the Adenomatous Polyposis Coli (APC) gene. We deleted APC chiefly from excitatory neurons in the mouse developing forebrain; the mice exhibited changes in synapse maturation and density, reduced social interest, increased repetitive behaviors, and learning deficits. In addition, we found molecular changes that define a novel role for APC in linking to and regulating the levels of particular proteins that function in synaptic adhesion complexes and signaling pathways that are required for normal learning and memory consolidation.
(more…)
MedicalResearch.com Interview with: Dr. Henrik Larsson PhD
Associate Professor
Department of Medical Epidemiology and Biostatistics
Karolinska Institute
Stockholm, Sweden
MedicalResearch: What are the main findings of the study?Dr. Larrson: We found no evidence for an overall increased rate of suicide related events associated with the use of stimulant or non-stimulant drug treatment for ADHD. If anything, the results pointed to a potential protective effect of drugs for ADHD on suicidal behaviour, particularly for stimulant drugs.
(more…)
MedicalResearch.com Interview with Carlos J. Rodriguez, MD, MPH
Department of Medicine and Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina
MedicalResearch: What are the main findings of the study?Dr. Rodriguez: As a clinician there is a notion suggesting that lower blood pressure is better but our current research to date is controversial and not conclusive. We wanted to study a large group of people with hypertension and see whether over 20 years of follow up, if a lower systolic blood pressure would be associated with lower cardiovascular events (heart attack, stroke, heart failure, angina). We hypothesized that there would be a linear association between blood pressure and events, that lower blood pressure would be associated with lower events and that as the blood pressure went up there would be more events. We found this was not the case but that hypertensives with a blood pressure between 120-138mmhg have the greatest benefit and those with a blood pressure less than 120mmhg did not have additional benefit.
(more…)
MedicalResearch.com Interview with:Alva O. Ferdinand, DrPH, JD
Texas A&M Health Science Center
School of Public Health
College Station, TX 77843
MedicalResearch: What are the main findings of the study?Answer: Over the last decade, several states have enacted legislating making it illegal to text while driving. However, little is known about the impact that state texting-while-driving bans have had on roadway crash-related fatalities. Some states have banned all drivers from texting while driving while others have banned only young drivers from this activity. Furthermore, some states’ texting bans entail secondary enforcement, meaning an enforcement officer must have another reason to stop a vehicle before citing a driver for texting while driving, and other states’ texting bans entail primary enforcement, meaning an enforcement officer does not have to have another reason for stopping a vehicle.
We conducted a longitudinal panel analysis examining within-state changes in roadway fatalities after the enactment of state texting-while-driving bans using roadway fatality data as captured in the Fatality Analysis Reporting System between 2000 and 2010. To further examined the impact of these bans on various age groups, as younger individuals are thought to engage in texting while driving more often than older individuals. States that had enacted texting-while-driving bans during the study period were considered “treatment” states and states that had not passed texting-while-driving bans were considered “control” states.
We found that states with primary laws banning young drivers only saw an average of an 11% reduction in roadway following the enactment of such bans during the study period. States with primary laws banning all drivers were also associated with significant reductions for those aged 15 to 21 and those who were 65 years old or older. States with secondarily enforced bans, whether banning all drivers or young drivers only, did not see any significant reductions in roadway fatalities.
(more…)
MedicalResearch.com Interview with: Nynne Nyboe Andersen, MD, PhD student
Department of Epidemiology Research
Statens Serum Institut
2300 Copenhagen, Denmark
MedicalResearch: What are the main findings of the study?Dr. Andersen: Previous studies evaluating the risk of cancer associated with the use of TNF-α antagonists are mainly based on data from randomized clinical trials with a short follow up time. Consequently, we used the national Danish registries to conduct a nationwide population-based cohort study assessing the risk of cancer in patients with inflammatory bowel disease (IBD) exposed to these drugs from their introduction in 1999 until 2012. We included more than 56.000 patients with IBD and among those 4500 were exposed to TNF-α antagonists, contributing with almost 20.000 person-years of follow-up.
Our main results revealed that the risk of overall cancer was significantly increased in the analysis adjusted for propensity score and potential confounders except for azathioprine, however, when we additionally adjusted for azathioprine use the relative risk decreased markedly leaving no significant increased risk of cancer. Given the upper limit of the confidence intervals, this study could rule out a more than 36% relative increase in the risk of overall cancer over a median follow-up of 3.7 years among TNF-α antagonist-exposed patients with 25% of these followed for 6 years or longer. We also did some stratified analyses according to cumulative number of TNF-α inhibitor doses, and time since first TNF-α inhibitor dose, but these results did not reveal any significantly increased risk of cancer nor did the analyses on site-specific cancers.
(more…)
MedicalResearch.com Interview with:David L. Brown, MD, FACC
Professor of Medicine
Cardiovascular Division
Washington University School of Medicine
St. Louis, MO 63110
MedicalResearch: What are the main findings of the study?Dr. Brown: This meta-analysis of randomized controlled trials showed that using a genotype-based warfarin dosing algorithm did not improve the process or outcomes of anticoagulation compared to using a clinical dosing algorithm.
(more…)
MedicalResearch.com Interview with: Yosuke Uchitomi, MD, PhD
Professor and Chairman,
Department of Neuropsychiatry,
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences,
Okayama, Japan
MedicalResearch: What are the main findings of the study?Dr. Uchitomi: This study demonstrated the effect of communication skills training (CST) consisted of didactic lecture, role-plays, and peer discussion for oncologists with extensive experience in comprehensive cancer center hospitals in improving the psychological distress of cancer patients as well as oncologist performances and confidence in communicating with patients, using a randomized design. Reasons for this positive result might include that the communication skills training program had been developed based on patient preferences regarding the communication of bad news and oncologists’ needs.
(more…)
MedicalResearch.com Interview with: Ronnie Fass, M.D., FACG, Professor of Medicine
Case Western Reserve University
Director, Division of Gastroenterology and Hepatology, Head, Esophageal and Swallowing Center, Metro Health Medical Center
Cleveland, OH
MedicalResearch: What are the main findings of the study?Dr. Fass: This is the first study to compare the extent of acid reflux between nighttime sleep and daytime naps in patients with Gastroesophageal reflux disease. The results of our study show that naps are associated with significantly greater esophageal acid exposure compared to sleep. Acid reflux events were more frequent and their total duration was longer during naps when compared with acid reflux events during nighttime sleep. Additionally, the fraction of time that the subjects were experiencing acid reflux with pH < 4 was significantly higher during naps than nighttime sleep and subjects experienced more symptoms due to acid reflux during their nap than their sleep.
(more…)
MedicalResearch.com Interview with: Professor Louis Appleby
Professor of Psychiatry C.B.E
The University of Manchester in the UK
MedicalResearch: What are the main findings of the study?Professor Appleby: “Patients with mental illness are two and a half times more likely to be victims of homicide than people in the general population according to our research published in The Lancet Psychiatry today.
“In this study, the National Confidential Inquiry into Suicide and Homicide by People with Mental Illness (NCI), based at The University of Manchester, examined data on the victims and perpetrators of all homicides in England and Wales between January, 2003 and December, 2005.
We found that during the 3-year study period, 1496 people were victims of homicide, and 6% (90) of them had been under the care of mental health services in the year before their death. A third (29) of these patient victims were killed by other patients with mental illness.
In 23 homicides in which the victim was a mental health patient killed by another mental health patient, the victim and the perpetrator were known to each other either as partners (9, 35%), family members (4, 15%), or acquaintances (10, 38%). In 21 of these 23 cases, both the victims and perpetrators were undergoing treatment at the same National Health Service Trust.
Alcohol and drug misuse (victims 66%, perpetrators 93%) and a history of violence (victims 24%, perpetrators 24%) were common among both patient victims and perpetrators. The study also found that in the 3 years to 2005, 213 mental health patients were convicted of homicide—accounting for 12% of all homicide convictions.”
(more…)
MedicalResearch.com Interview with: Sergio R. Ojeda, D.V.M.
Division Head and Senior Scientist Division of Neuroscience
Division of Neuroscience, OR National Primate Research Center/Oregon Health and Science University,
Beaverton OR 97006
MedicalResearch: What are the main findings of the study?Dr. Ojeda:The study shows that a receptor for two growth factors (brain-derived neurotrophic factor [BDNF] and neurotrophin 4/5 [NT4/5]) that are known to be important for development of the nervous system is also essential for maintaining oocyte integrity and survival in the mammalian ovary. Intriguingly, the full-length form of this receptor (known as NTRK2-FL) is not expressed in oocytes until the time of the first ovulation. At this time, the pre-ovulatory gonadotropin discharge stimulates granulosa cells of ovarian follicles to produce not only more BDNF, but also more of a peptide known as kisspeptin, to induce the formation of NTRK2-FL in oocytes. To date, kisspeptin was known to be only critical for the hypothalamic control of reproduction. To induce NTRK2-FL, BDNF binds to truncated NTRK2 receptors (NTRK2-T1), which are abundant in oocytes throughout prepubertal development. Kisspeptin, on the other hand, does so by activating its receptor KISS1R, also expressed in oocytes. Once present after the first ovulation, NTRK2-FL is able to activate a survival pathway in oocytes following gonadotropin stimulation, presumably at every cycle. In the absence of NTRK2-FL, oocytes die, follicular structure disintegrates and a condition of premature ovarian failure ensues.
(more…)
MedicalResearch.com Interview with: Monika Waszczuk
1+3 PhD Student
MRC SGDP Research Centre
Institute of Psychiatry, King's College London
DeCrespigny Park London UK
MedicalResearch: What are the main findings of the study?Answer:Little is known about the genetic influences on the relationship between depression and anxiety disorders across development. We used two population-based prospective longitudinal twin and sibling studies to investigate phenotypic associations between the symptoms of these disorders, and tested genetic structures underlying these symptoms across three developmental stages: childhood, adolescence and early adulthood.
We found that depression and anxiety disorder symptoms are largely distinct in childhood and are influenced by largely independent genetic factors. Depression and anxiety symptoms become more associated and shared most of their genetic etiology from adolescence. An overarching internalizing genetic factor influencing depression and all anxiety subscales emerged in early adulthood. These results provide preliminary evidence for different phenotypic and genetic structures of internalizing disorder symptoms in childhood, adolescence and young adulthood, with depression and anxiety becoming more associated from adolescence.
(more…)
MedicalResearch.com Interview with: Jack Cuzick PhD
Centre for Cancer Prevention
Wolfson Institute of Preventive Medicine
Queen Mary University of London,
London UK
Dr. Cuzick offers the manuscript below to put the results of the Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial in focus for MedicalResearch.com.
The Prevention of Breast Cancer
The first human evidence that drug treatment might reduce the incidence of breast cancer was reported in 19851, where it was found that use of tamoxifen in a trial of women with breast cancer to reduce recurrence of existing tumours also had a major impact on new tumours in the opposite breast, reducing them from 10 to 3. That observation has subsequently been confirmed in several other adjuvant trials and an overview of all such trials indicates that after an average of about 8 years of follow up, 5 years of tamoxifen reduced new contralateral tumours by 39%, with similar effects in years 0-5 and 5-10 in women with oestrogen receptor positive or unknown primary tumours2. These observations and positive results from animal studies3, led to the evaluation of 5 years of tamoxifen in women without breast cancer, but at high risk in 4 large trials. A recent overview4 indicates a 33% reduction in all breast cancer after a 10 years follow up, with a larger reduction in years 0-5 (48%), when treatment was given, and a continuing (22%) effect in years 5-10. Reductions were seen for oestrogen receptor positive invasive cancer (44%) and DCIS (28%), but no effect was seen for both oestrogen receptor negative invasive cancer, where in fact a non-significant 13% (P=0.4) increase was observed. Somewhat larger effects were seen for these other selective estrogen receptor modulators (SERMs) – raloxifene, lasofoxifene and arzoxifene – in trials of osteoporotic women, where the primary endpoint was fracture reduction4. A subsequent head-to-head trial of raloxifene vs tamoxifen, showed tamoxifen to be about 20% more effective, but raloxifene had fewer side effects5. Lasofoxifene not only showed benefits for breast cancer reduction but also reduced fracture rates and heart disease6, and this multi-dimensional set of benefits makes it an attractive candidate for prevention.
(more…)
MedicalResearch Interview with: Jay Giri, MD MPH
Assistant Professor, Perelman School of Medicine
Director, Peripheral Intervention
Interventional Cardiology & Vascular Medicine
Cardiovascular Division
University of Pennsylvania
MedicalResearch: What are the main findings of the study?Dr. Giri: Use of thrombolytics was associated with lower all-cause mortality and increased rates of intracranial hemorrhage. These results were also seen in intermediate-risk pulmonary embolism. Finally, it appeared that patients under age 65 might be at less bleeding risk from thrombolytics.
(more…)
MedicalResearch.com Interview with:Professor June-Hong Kim, Division of Cardiology
Department of Internal Medicine and Research Institute for Convergence of Biomedical Science and Technology,
Pusan National University Yangsan Hospital
Yangsan, South Korea;
MedicalResearch: What are the main findings of the study?Dr. Kim: In vasospastic angina, the cilostazol group significantly reduced relative ireduction of of weekly incidence of chest pain compared with placebo group (−66.5±88.6% vs −17.6±140.1%, respectively, p=0.009).. Other clinical parameters such as a change in the frequency of chest pain (−3.7±0.5 vs −1.9±0.6, respectively, p=0.029), a change in the chest pain severity scale (−2.8±0.4 vs −1.1±0.4, respectively, p=0.003), and the proportion of chest pain-free patients (76.0% vs 33.3%, respectively, p=0.003) also significantly favored cilostazol. (more…)
MedicalResearch.com Interview withProf. Julia I. Newton:
Dean of Clinical Medicine & Professor of Ageing and Medicine
Clinical Academic Office
The Medical School
Newcastle University
MedicalResearch: What are the main findings of the study?Prof. Newton: In this study we have explored for the first time the characteristics of patients with Postural tachycardia in the UK
Postural Tachycardia Syndrome patients are predominantly female, young, well educated and have significant and debilitating symptoms that impact significantly upon their quality of life.
Despite this, there is no consistent treatment, high levels of disability and associated comorbidity.
Although individuals presented with symptoms at the same age, those attending a specialist clinic received a diagnosis quicker.
Symptom burden for those with Postural tachycardia is high and comparable to that seen in Chronic Fatigue Syndrome.
Chronic Fatigue Syndrome is recognized by the WHO as a neurological disorder and by the Disability Discrimination Act 2005 as a disability. At the current time those with Postural Tachycardia Syndrome suffer to the same extent as those with Chronic Fatigue Syndrome but do not receive the same protection from the law.
It is important that more work is done to understand the underlying autonomic abnormality in those with Postural Tachycardia Syndrome in order to allow us to develop targeted treatments that are effective and go beyond the currently available simply symptomatic management.
MedicalResearch.com Interview with:
Greg D. Sacks, MD, MPH
Department of Surgery, David Geffen School of Medicine at UCLAMedicalResearch: What are the main findings of this study?
Dr. Sacks: This study evaluated the all-cause readmissions measure developed by the Centers for Medicare and Medicaid Services to penalize hospitals for unplanned readmissions. By evaluating readmissions of surgical patients at a single academic medical center, we found that the readmissions measure was able to identify only a third of the planned readmissions and mislabeled the remaining two thirds of planned readmissions as unplanned. This discrepancy was a result of the measure’s reliance on administrative claims data, which disagreed in 31% of cases with clinical data abstracted from the patient’s chart. Also, almost a third (27%) of the readmissions in this study were for reasons unrelated to the original hospitalization.
(more…)
MedicalResearch.com Interview with: David J.A. Jenkins
Professor and Canada Research Chair in Nutrition and Metabolism,
Dept. of Medicine and Nutritional Sciences, Faculty of Medicine,
University of Toronto, Toronto, ON, Canada
MedicalResearch: What are the main findings of the study?Prof. Jenkins: The main findings were that inclusion of just over an once (31g) of canola oil in low glycemic index diets of type 2 diabetes study participants, to further reduce the glycemic load (GL), reduced HbAIC more than a high cereal fiber diet, as predicted. However the Canola oil low GL diet also reduced serum TG and LDL-C and thus Framingham risk score for cardiovascular disease. The effect was seen most clearly in those at highest CHD risk and those with features of the metabolic syndrome.
(more…)
MedicalResearch.com Interview with: Michelle A. Mendez, PhD
Assistant Professor
Department of Nutrition
University of North Carolina at Chapel Hill
Gillings School of Public Health
Chapel Hill, NC
MedicalResearch: What are the main findings of the study?Dr. Mendez: Using national surveillance data to examine trends in energy intake among children, we found that there was an initial decline in intakes from 2003-4 through 2007-08, which mirrored evidence that child obesity in the US may have begun to decline in that period. Subsequently, however, in 2009-10, energy intake increased in older children aged 12-19y, and reached a plateau in children aged <11y. This shift is consistent with reports that, particularly in older children, the downward trend in obesity levels may have been reversed in recent years.
(more…)
MedicalResearch.com Interview with:Dr. Richard D. CarvajalMD
Director, Developmental Therapeutics; Elizabeth and Felix Rohatyn Chair for Junior Faculty
Memorial Sloan Kettering Cancer Center
MedicalResearch: What are the main findings of the study?Dr. Carvajal: This is the first study to show that a systemic therapy provides significant clinical benefit in a randomized fashion to patients with advanced uveal melanoma, a population of patients who have very limited treatment options. This clinical benefit has never previously been demonstrated with other agents, both conventional or investigational.
(more…)
MedicalResearch.com Interview with: Gerard Ngueta
Population Health and Optimal Health Practices Research Unit,
CHU de Québec Research Centre, Québec
Québec, Canada
MedicalResearch: What are the main findings of the study?Answer: The main findings of our study are as follows :
1- Contrary to body mass index (BMI), the waist circumference alone (which indicate central obesity or fat distribution) is not associated with cardiometabolic factors under study (i.e., insulin, triglycerides, systolic blood pressure and high-density lipoproteins levels). Thus, the apparent association –as found in previous studies- appears to be mediated through overall obesity (i.e., BMI). In the other words, the association observed in the previous studies between waist circumference and the cardiometabolic risk factors cited above could be mainly due to the strong correlation between waist circumference and BMI.
2- It is possible to estimate the independent contribution of overall fat and central fat on cardiometabolic risk factors by applying the residual model as previously suggested by Willet and Stampfer.
(more…)
MedicalResearch.com Interview with L. Keoki Williams, MD, MPH
Center for Health Policy and Health Services Research
Department of Internal Medicine
Henry Ford Health System
Detroit, Michigan 48104
MedicalResearch: What are the main findings of the study?Dr. Williams: Metformin is recommended as first line treatment for type 2 diabetes, and these recommendations are based on the results of clinical trials performed almost exclusively in white individuals. This is the first study to specifically assess whether metformin is effective at reducing blood glucose levels in African American individuals. In our large study of over 19,000 individuals, we showed that metformin was consistently more effective at reducing glycated hemoglobin (HbA1c) levels (a measure of long-term blood glucose control) in African Americans when compared with white individuals.
(more…)
MedicalResearch.com Interview with: Peter Stein, M.D.
Vice president, Clinical Research for Diabetes and Dndocrinology
Merck Research Laboratories.
MedicalResearch: What are the main findings of the study?Dr. Stein: This late-breaking observational study assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combination of JANUVIA® (sitagliptin) and metformin, and patients taking the combination of a sulfonylurea and metformin. In this study, patients treated with a combination of JANUVIA and metformin initiated insulin therapy at a slower rate during the period of observation than patients treated with a combination of sulfonylurea and metformin.
In this study, the percentages of patients initiating insulin by years one through six were 3.6, 8.4, 12.9, 17.7, 22.4, 26.6 for patients taking JANUVIA; and 4.1, 9.4, 14.6, 21.0, 27.1, 34.1 for patients taking a sulfonylurea. An analysis of the data overall (Kaplan-Meier method) showed that patients taking JANUVIA progressed more slowly to insulin use than patients taking a sulfonylurea (p=0.0034). The Cox proportional hazard regression analysis indicated that by year six, patients in the JANUVIA group were 24 percent less likely to initiate insulin during the period of observation compared to patients taking a sulfonylurea (HR = 0.76; p = 0.0011).
Similar results were observed in the sub-group of patients with a baseline A1C of less than 9 percent (HR = 0.77; p = 0.0128]; however there was no statistically significant difference in time to insulin initiation in the sub-group with a baseline A1C of greater than or equal to 9 percent (HR = 0.75; p = 0.1818).
(more…)
MedicalResearch.com: Interview with Tapan Mehta, Ph.D.
Assistant Professor
School of Health Professions
University of Alabama at Birmingham
MedicalResearch: What are the main findings of the study?Dr. Mehta: Grade 1 obesity’s (body mass index [BMI] 30 to < 35) association with reduced longevity has lessened over calendar time for older white men (age >60) but not for younger middle aged (age ≤60) men. For white women, there is evidence of a decline in the association of obesity, both for Grade 1 obesity and grade 2-3 obesity (BMI ≥35), with reduced longevity across all adult ages.
To the extent that these associations can be taken as indicators of causation, this implies that the harmfulness of obesity-mortality association has declined over calendar time in white women across all ages. However, the decline in the harmfulness of obesity-mortality association is limited to older grade 1 obese white men.
(more…)
MedicalResearch.com: Interview with:Dr. Patrick Le Goux
Rheumatologist Hôpitaux universitaires Paris Ouest France
French Tennis Federation medical staff
MedicalResearch: What are the main findings of the study?Dr. Le Goux: The therapeutic effect of platelet-rich plasma (PRP) of two ultrasound guided PRP injections at 4 weeks interval compared to two saline injections (as placebo or treatment of reference) is similar on a visual analogic scale for epicondylitis of recent evolution (3 months duration maximum) in a prospective randomized double blind study with 12 months follow up. We have no intrinsic or inherent benefit of the PRP injections.
(more…)
MedicalResearch.com Interview withDr. Stuart Gordon MD
Gastroenterologist
Henry Ford Hospital
Detroit, MI 48202.
MedicalResearch: What are the main findings of the study?Dr. Gordon: In a large American cohort of Hepatitis B patients, those who took antiviral therapy had a significantly lower risk of developing liver cancer than those who did not take such therapy.
(more…)
MedicalResearch.com Interview with:Julio A. Chirinos, MD, PhD
Assistant Professor of Medicine
Director, CTRC Cardiovascular Phenotyping Unit
Perelman School of Medicine, University of Pennsylvania
Director of Non-Invasive Imaging
Philadelphia VA Medical Center
MedicalResearch: What are the main findings of the study?Dr. Chirinos: The main findings of the study is that, among patients with obesity and moderate to severe obstructive sleep apnea, obesity, rather than OSA, appears to be the primary cause of inflammation, insulin resistance and dyslipidemia. However, both obesity and obstructive sleep apnea appear to be causally related to hypertension. In this population, weight loss, but not CPAP, can be expected to reduce the burden of inflammation, insulin resistance and dyslipidemia. However, CPAP, among patients who comply with therapy, can be expected to provide a significant incremental benefit on blood pressure. The latter is an important potential benefit of CPAP and should not be disregarded.
(more…)
MedicalResearch.com Interview with: Evan Thacker PhD
Brigham Young University
Provo, Utah
MedicalResearch: What are the main findings of the study?Dr. Thacker:In this study of over 17,000 American adults aged 45 and above, we first measured people’s cardiovascular health based on their smoking habits, diet, physical activity, body weight, blood pressure, blood cholesterol, and blood sugar. We then tracked these people for several years with cognitive function tests which measure memory and thinking abilities. The main finding of our study was that people who had the lowest levels of cardiovascular health at the beginning of the study were more likely to experience cognitive impairment – poor performance on the cognitive function tests – at the end of the study. People who had medium to high levels of cardiovascular health were less likely to experience cognitive impairment.
(more…)
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptRejectRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.